SLDB, US83422E2046

Solid Biosciences stock fell 1.86 percent on October 2

Published on 10/05/2026 at 12:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Solid Biosciences granted 8,150 RSUs on October 1, 2026, while RBC set an USD 18 target on September 16. Q2 EPS of USD -0.38 beat consensus.

SLDB, US83422E2046, Illustration mit AI erstellt.

Solid Biosciences (ISIN US83422E2046) stock was last at USD 6.85 on Nasdaq on October 2, 2026, down 1.86 percent from the prior session. On October 1, 2026, Solid Biosciences announced 8,150 restricted stock units for one newly hired employee, making the grant the latest company-specific event for investors. The shares traded 40.17 percent below their 52-week high of USD 11.45.

October grant adds a fresh company event

The RSUs will vest in four equal installments on the first four anniversaries of the October 1 grant date, subject to continued employment. The award came under Solid Biosciences' 2024 Inducement Stock Incentive Plan and complied with Nasdaq Listing Rule 5635(c)(4), according to the company release linked above.

The grant is small relative to the company valuation, but it provides a dated operational signal while the investment case remains tied to clinical development. Solid Biosciences is developing genetic medicines for neuromuscular and cardiac diseases, including programs for Duchenne muscular dystrophy and inherited cardiac conditions.

Second-quarter loss beat estimates

Solid Biosciences reported second-quarter EPS of USD -0.38 for the period ended June 30, 2026, versus a USD -0.46 consensus estimate. Nasdaq also reported quarterly revenue of USD 0.00 and identified August 6, 2026, as the earnings release date.

The comparison matters because the company remains in a development-heavy phase: the reported loss was USD 0.08 better than consensus, while revenue did not provide an offsetting contribution. Operating cash flow was negative USD 52.587 million in the second quarter of 2026, according to the standardized financial statement data for the period.

Analyst targets exceed the last quote

Nasdaq reported that RBC Capital initiated coverage on September 16, 2026, with an Outperform rating and an USD 18 price target. The same report placed the consensus mean target at USD 19.38 as of September 15, 2026, with a median of USD 18.87 across 19 recommendations; the mean stood 131.54 percent above the USD 8.37 reference close used in that report.

The target gap highlights the market's dependence on clinical and regulatory execution rather than current revenue. For investors, the key contrast is measurable: a USD 6.85 last quote on October 2, 2026, against an analyst consensus mean of USD 19.38 and a second-quarter loss of USD 0.38 per share.

SLDB trades below its yearly high

On October 2, 2026, SLDB was last at USD 6.85 on Nasdaq at 4:00 p.m. ET, down USD 0.13 or 1.86 percent, with 1,198,189 shares traded. Its 52-week range was USD 3.79 to USD 11.45, and market capitalization was USD 674.4 million as of the same quote date.